depura
sanofi-aventis farmacÊutica ltda - colecalciferol - vitamina d e anÁlogos
depura
sanofi medley farmacÊutica ltda. - colecalciferol - vitamina d e anÁlogos
depura
sanofi-aventis farmacÊutica ltda - colecalciferol - vitaminas
depura
sanofi medley farmacÊutica ltda. - colecalciferol - vitaminas
androcur depot 300 mg/3 ml solução injetável
bayer portugal, lda. - ciproterona - solução injetável - 300 mg/3 ml - ciproterona, acetato 100 mg/ml - cyproterone - n/a - duração do tratamento: longa duração
depotyl la 150mg/ml
norbrook laboratories ltd (irlanda do norte) - tilosina - suspensão injetável - tilosina - suínos
resolor
takeda pharmaceuticals international ag ireland - prucalopride succinato - prisão de ventre - outras drogas para constipação - resolor é indicado para o tratamento sintomático da constipação crônica em adultos em que os laxantes não proporcionam alívio adequado.
vazkepa
amarin pharmaceuticals ireland limited - icosapent ethyl - deslipidemias - agentes modificadores de lipídios - indicated to reduce cardiovascular risk as an adjunct to statin therapy.
kalydeco
vertex pharmaceuticals (ireland) limited - ivacaftor - fibrose cística - outros produtos do sistema respiratório - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 e 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 e 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
orkambi
vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - fibrose cística - outros produtos do sistema respiratório - orkambi comprimidos são indicados para o tratamento da fibrose cística (fc) em pacientes com idade entre 6 anos e mais velhos que são homozigotos para a mutação f508del no gene cftr. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.